BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more
BioGaia AB (publ) (BIOG-B) - Net Assets
Latest net assets as of September 2025: Skr1.22 Billion SEK
Based on the latest financial reports, BioGaia AB (publ) (BIOG-B) has net assets worth Skr1.22 Billion SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr1.49 Billion) and total liabilities (Skr269.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.22 Billion |
| % of Total Assets | 81.91% |
| Annual Growth Rate | 12.55% |
| 5-Year Change | -1.28% |
| 10-Year Change | 335.52% |
| Growth Volatility | 55.04 |
BioGaia AB (publ) - Net Assets Trend (2002–2024)
This chart illustrates how BioGaia AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioGaia AB (publ) (2002–2024)
The table below shows the annual net assets of BioGaia AB (publ) from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr1.72 Billion | -15.09% |
| 2023-12-31 | Skr2.03 Billion | +2.94% |
| 2022-12-31 | Skr1.97 Billion | +5.06% |
| 2021-12-31 | Skr1.88 Billion | +7.51% |
| 2020-12-31 | Skr1.75 Billion | +243.83% |
| 2019-12-31 | Skr507.87 Million | -0.05% |
| 2018-12-31 | Skr508.12 Million | +9.54% |
| 2017-12-31 | Skr463.89 Million | +11.73% |
| 2016-12-31 | Skr415.18 Million | +4.89% |
| 2015-12-31 | Skr395.83 Million | +14.87% |
| 2014-12-31 | Skr344.59 Million | +8.75% |
| 2013-12-31 | Skr316.86 Million | -30.63% |
| 2012-12-31 | Skr456.79 Million | +98.30% |
| 2011-12-31 | Skr230.35 Million | +22.97% |
| 2010-12-31 | Skr187.32 Million | +16.26% |
| 2009-12-31 | Skr161.12 Million | +21.67% |
| 2008-12-31 | Skr132.42 Million | +39.52% |
| 2007-12-31 | Skr94.91 Million | +27.34% |
| 2006-12-31 | Skr74.53 Million | +3.83% |
| 2005-12-31 | Skr71.78 Million | -21.55% |
| 2004-12-31 | Skr91.50 Million | -20.33% |
| 2003-12-31 | Skr114.85 Million | -10.27% |
| 2002-12-31 | Skr127.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioGaia AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 175.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr491.04 Million | 28.48% |
| Common Stock | Skr20.23 Million | 1.17% |
| Other Comprehensive Income | Skr38.50 Million | 2.23% |
| Other Components | Skr1.17 Billion | 68.11% |
| Total Equity | Skr1.72 Billion | 100.00% |
BioGaia AB (publ) Competitors by Market Cap
The table below lists competitors of BioGaia AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GQG PARTNERS CDI/1/1
F:6P1
|
$714.87 Million |
|
Zhejiang Zhaolong Interconnect Technology Co. Limited
SHE:300913
|
$714.98 Million |
|
Xiangyang Changyuan Donggu Industry Co Ltd
SHG:603950
|
$715.16 Million |
|
Beijing Join-Cheer Software Co Ltd
SHE:002279
|
$715.72 Million |
|
BYTES TECH.GRP LS -01
F:9NY
|
$714.57 Million |
|
Ta Ya Electric Wire & Cable Co., Ltd.
TW:1609
|
$714.51 Million |
|
GRAY TELEVISION A DL-01
F:GCZA
|
$714.50 Million |
|
Nanosonics Limited
PINK:NNCSF
|
$714.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioGaia AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,030,342,000 to 1,723,932,000, a change of -306,410,000 (-15.1%).
- Net income of 351,388,000 contributed positively to equity growth.
- Dividend payments of 696,778,000 reduced retained earnings.
- Share repurchases of 20,815,000 reduced equity.
- New share issuances of 20,815,000 increased equity.
- Other comprehensive income increased equity by 22,565,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr351.39 Million | +20.38% |
| Dividends Paid | Skr696.78 Million | -40.42% |
| Share Repurchases | Skr20.82 Million | -1.21% |
| Share Issuances | Skr20.82 Million | +1.21% |
| Other Comprehensive Income | Skr22.57 Million | +1.31% |
| Other Changes | Skr16.41 Million | +0.95% |
| Total Change | Skr- | -15.09% |
Book Value vs Market Value Analysis
This analysis compares BioGaia AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 76.45x to 6.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr1.48 | Skr113.40 | x |
| 2003-12-31 | Skr1.34 | Skr113.40 | x |
| 2004-12-31 | Skr1.06 | Skr113.40 | x |
| 2005-12-31 | Skr0.83 | Skr113.40 | x |
| 2006-12-31 | Skr0.87 | Skr113.40 | x |
| 2007-12-31 | Skr1.10 | Skr113.40 | x |
| 2008-12-31 | Skr1.54 | Skr113.40 | x |
| 2009-12-31 | Skr1.86 | Skr113.40 | x |
| 2010-12-31 | Skr2.17 | Skr113.40 | x |
| 2011-12-31 | Skr2.66 | Skr113.40 | x |
| 2012-12-31 | Skr5.25 | Skr113.40 | x |
| 2013-12-31 | Skr3.66 | Skr113.40 | x |
| 2014-12-31 | Skr3.99 | Skr113.40 | x |
| 2015-12-31 | Skr4.57 | Skr113.40 | x |
| 2016-12-31 | Skr4.79 | Skr113.40 | x |
| 2017-12-31 | Skr5.35 | Skr113.40 | x |
| 2018-12-31 | Skr5.83 | Skr113.40 | x |
| 2019-12-31 | Skr5.86 | Skr113.40 | x |
| 2020-12-31 | Skr17.29 | Skr113.40 | x |
| 2021-12-31 | Skr18.59 | Skr113.40 | x |
| 2022-12-31 | Skr19.53 | Skr113.40 | x |
| 2023-12-31 | Skr20.11 | Skr113.40 | x |
| 2024-12-31 | Skr17.06 | Skr113.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioGaia AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.38%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.70%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.18x
- Recent ROE (20.38%) is below the historical average (25.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 30.13% | 89.46% | 0.27x | 1.26x | Skr25.76 Million |
| 2003 | 11.37% | 36.62% | 0.26x | 1.18x | Skr1.57 Million |
| 2004 | 25.41% | 57.50% | 0.37x | 1.19x | Skr14.10 Million |
| 2005 | -27.62% | -33.26% | 0.68x | 1.21x | Skr-27.00 Million |
| 2006 | 3.65% | 3.13% | 0.96x | 1.22x | Skr-4.73 Million |
| 2007 | 20.71% | 18.45% | 0.96x | 1.17x | Skr10.17 Million |
| 2008 | 27.28% | 24.88% | 0.94x | 1.17x | Skr22.88 Million |
| 2009 | 22.35% | 17.72% | 1.13x | 1.11x | Skr19.92 Million |
| 2010 | 25.19% | 19.98% | 1.04x | 1.22x | Skr28.45 Million |
| 2011 | 33.24% | 24.24% | 1.13x | 1.22x | Skr53.39 Million |
| 2012 | 72.13% | 50.67% | 1.25x | 1.14x | Skr281.64 Million |
| 2013 | 19.45% | 19.54% | 0.82x | 1.21x | Skr29.99 Million |
| 2014 | 42.79% | 30.59% | 1.16x | 1.21x | Skr112.96 Million |
| 2015 | 30.67% | 25.12% | 1.02x | 1.20x | Skr81.82 Million |
| 2016 | 54.81% | 42.56% | 1.09x | 1.18x | Skr186.05 Million |
| 2017 | 38.92% | 29.36% | 1.07x | 1.24x | Skr134.17 Million |
| 2018 | 42.55% | 28.97% | 1.12x | 1.31x | Skr164.39 Million |
| 2019 | 36.89% | 24.38% | 1.15x | 1.31x | Skr136.56 Million |
| 2020 | 10.29% | 24.06% | 0.39x | 1.10x | Skr5.11 Million |
| 2021 | 10.45% | 25.00% | 0.37x | 1.13x | Skr8.54 Million |
| 2022 | 18.95% | 33.86% | 0.50x | 1.12x | Skr176.53 Million |
| 2023 | 17.99% | 28.18% | 0.56x | 1.15x | Skr162.32 Million |
| 2024 | 20.38% | 24.70% | 0.70x | 1.18x | Skr178.99 Million |
Industry Comparison
This section compares BioGaia AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $79,875,046
- Average return on equity (ROE) among peers: -66.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioGaia AB (publ) (BIOG-B) | Skr1.22 Billion | 30.13% | 0.22x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $20.94 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $15.08 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |